Health: FDA News

Today is March 19, 2024. All times in Eastern Daylight Time.

Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

03/18/2024 - 03:32 PM

BUSINESS WIRE
World’s First Total Knee Replacement Patient Treated with PolarisAR Breakthrough Mixed-Reality Surgical Guidance System

03/18/2024 - 09:01 AM

BUSINESS WIRE
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

03/18/2024 - 08:00 AM

BUSINESS WIRE
Alliance for Food and Farming: Studies, Government Data Discredit “Dirty Dozen” List

03/18/2024 - 08:00 AM

BUSINESS WIRE
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

03/18/2024 - 08:00 AM

BUSINESS WIRE
Avenacy Announces New Product Launches and Participation in DCAT Week 2024

03/18/2024 - 07:00 AM

BUSINESS WIRE
BeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得

03/16/2024 - 11:18 AM

BUSINESS WIRE
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

03/15/2024 - 06:27 PM

BUSINESS WIRE
百濟神州喜獲FDA批准，TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療

03/15/2024 - 05:13 PM

BUSINESS WIRE
BeiGene recebe aprovação da FDA para TEVIMBRA® para tratamento de câncer espinocelular de esôfago avançado ou metastático após quimioterapia prévia

03/15/2024 - 04:02 PM

BUSINESS WIRE
BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie

03/15/2024 - 04:02 PM

BUSINESS WIRE
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

03/15/2024 - 03:15 PM

BUSINESS WIRE
BeiGene recibe la aprobación de la FDA para TEVIMBRA ® para el tratamiento del carcinoma esofágico de células escamosas avanzado o metastásico luego de una quimioterapia previa

03/15/2024 - 10:41 AM

BUSINESS WIRE
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

03/15/2024 - 07:30 AM

BUSINESS WIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

03/15/2024 - 06:45 AM

BUSINESS WIRE
BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger Chemotherapie

03/15/2024 - 02:06 AM

BUSINESS WIRE
Riassunto: BeiGene riceve l’autorizzazione da parte della FDA all’uso di TEVIMBRA® per il trattamento del carcinoma esofageo a cellule squamose metastatico o avanzato successivo alla chemioterapia

03/15/2024 - 02:00 AM

BUSINESS WIRE
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

03/14/2024 - 09:35 PM

BUSINESS WIRE
Samenvatting: BeiGene ontvangt FDA-goedkeuring voor TEVIMBRA ®voor de behandeling van gevorderd of gemetastaseerd plaveiselcelcarcinoom van de slokdarm na eerdere chemotherapie

03/14/2024 - 07:20 PM

BUSINESS WIRE
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3

03/14/2024 - 05:48 PM

BUSINESS WIRE
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3

03/14/2024 - 04:28 PM

BUSINESS WIRE
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

03/14/2024 - 04:28 PM

BUSINESS WIRE
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

03/14/2024 - 03:54 PM

BUSINESS WIRE
Cybin anuncia una reunión positivo de fin de fase 2 con la FDA para el uso de CYB003 en el trastorno depresivo mayor, así como el diseño del programa de fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE
Cybin kondigt positieve vergadering aan het einde van Fase 2 met FDA aan voor CYB003 bij depressieve stoornissen en het programmaontwerp voor Fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE

1 2 3 4 5 6 7 8

Next »

Search